CellPly

Founded in 2018 and based in Milan, Cellply is a private, deep-tech company focused on automating single-cell analysis for the cell therapy and immuno-oncology markets. Its core technology is the VivaCyte platform, which leverages patented microfluidics to create and analyze tens of thousands of miniature co-cultures, providing multiplexed functional data on immune cells. The company is pre-revenue, targeting biopharma clients with a platform designed to accelerate drug discovery and process development for advanced cancer therapies.

Patented microfluidic Co-Culture Array (CC-Array) technology enabling automated, high-throughput, multiplexed functional analysis of single immune cells within biologically relevant co-cultures. The VivaCyte platform features open microwells for dynamic liquid exchange and configurable workflows for cell delivery, staining, stimulation, and AI-based imaging.

Cellply competes in the single-cell analysis and cell therapy tools space against companies like 10x Genomics (genomics-focused), Sartorius (incucyte live-cell analysis), and former players like Berkeley Lights. Its differentiation lies in its specific focus on automated, functional co-culture assays at nanoliter scale, a niche not fully addressed by current market leaders.